Business
Kite is developing a CAR-T, or chimeric antigen receptor T-cell therapy, which harnesses the body's immune cells to recognize and attack malignant cells.
Hi, what are you looking for?
Kite is developing a CAR-T, or chimeric antigen receptor T-cell therapy, which harnesses the body's immune cells to recognize and attack malignant cells.
The New York Stock Exchange began reopening its two equity venues that were shut down for hours today by a computer malfunction.
Teva is now close to the 4.6% stake in Mylan that will give it standing in the Netherlands courts.
The main beneficiary of the medical device company's IPO was Mori Arkin and Uri Geiger's Accelmed with a 9% stake.
The rejection assists Teva's $41 billion bid for Mylan, which is contingent on the Perrigo deal not going ahead.
Herbalife statement: Campaign that is reportedly under criminal investigation by the FBI and the Department of Justice
– Israel’s MobilEye is gearing up for its IPO in New York. – Israeli company MobilEye, which develops a collision warning system...
– Ellison, is reportedly ready to pay around $5 billion for the Columbia, Maryland based software developer. – – Larry Ellison, founder and...
– Stoppelman, co-founder and CEO of online city guide Yelp, intends to increase his foothold in Europe, with the launching pad to be based...